INTRODUCTION
Peroxisome proliferator-activated receptors (PPARS) belong to the nuclear hormone receptor superfamily of ligand activated transcription factors which includes steroids, thyroid, and retinoid hormones receptors (10) . Upon ligand binding, PPARs become transcriptionally active and alter the expression of target genes. PPAR is expressed in vascular endothelial cells and has been shown to inhibit atherosclerosis (34) . It has been shown that PPAR activation reduces the development of hypercholesterolemia induced atherosclerotic lesion formation in LDL receptor knock out mice (13) . In humans, PPAR activation reduces carotid intimal thickening, and neointimal formation after coronary artery stent placement in both diabetic and non-diabetic patients (15, 26, 28) . Calnek et al. have shown that PPAR ligands stimulate nitric oxide (NO) release from endothelial cells through a transcriptional mechanism unrelated to endothelial nitric oxide synthase (eNOS) expression (5) . In mice over-expressing both human renin and angiotensinogen, rosiglitazone lowered blood pressure and improved vasorelaxation response to acethylcholine without altering eNOS expression (18) . Taken together, these reports indicate that PPAR activation modulates eNOS activity through mechanisms which are not fully understood.
Previous studies suggest that L-arginine, as the sole precursor for NO generation, governs NOS activity (11, 32) . Among several transporters which mediate L-arginine uptake, cationic amino acid transporter-1 (CAT-1) is considered as the predominant arginine supplier for eNOS (14, 20) . Endothelial dysfunction (ECD) is a common denominator of chronic renal failure. Accumulated evidence indicate that ECD is linked to impaired capacity of the constitutive, Ca 2+ /calmodulin sensitive NO synthase (eNOS) to generate adequate quantities of NO (1, 6, 7, 21, 22) .
were treated with GW9662 (1 mg/kg/day ip) or vehicle (10% dimethyl sulfoxide) for 7 days before sacrifice.
Creatinine clearance and 24 hours protein excretion were measured prior to sacrifice, in all experimental groups as previously described (8) . Rats were euthanized using CO 2 .
Assessment of C-GMP generation
Aortic tissue cGMP generation was determined by ELISA. Isolated aortic rings were suspended in HEPES buffer to which a phosphodiesterase inhibitor (3-isobutyl-1-methylxantine 1mM) was included to inhibit cGMP degradation. Aliquates were incubated and shaken at 37 0 C for 10 minutes after which they were subjected to Carbamyl Choline (100 µM), a selective eNOS agonist for additional 5 minutes. Following incubation the samples were rapidly frozen and then homogenized in Trichloroacetate (TCA) 5% at 4 0 C.
The precipitate was removed by centrifugation (3000 rpm, 10 minutes) and TCA was ether extracted. Residual ether was removed by heating the samples for 5 minutes at 70 0 C. The samples were then processed for measurement of cGMP by ELISA kit (R&D systems). Each experiment was repeated 4 times.
L-Arginine uptake by Aortic rings
Uptake of radiolabelled L-arginine in the rat aorta was measured according to previously described methods with modification (23) . Immediately after sacrifice, the aorta was carefully excised from the left renal artery to the aortic valve ring and placed in ice-cold HEPES. The vessels were dissected free from adherent connective tissue and cut into rings (length 3 to 4mm). Each segment was cut longitudinally in half. To determine arginine transport, aortic segments from each experimental group were incubated and shaken for 10 minutes in HEPES buffer at pH 7.4, 37 0 C. L-[H 3 ] arginine and L-arginine, in a final concentration of 1mM, were added to a total volume of 2 ml for additional 1 minute. The duration of one minute was chosen since it was within the linear portion of uptake curves (data not shown). Transport was terminated by rapidly washing the aortic rings with ice cold PBS buffer (4 times, 3 ml/tube). The rings were then dried and solubilized in 1 ml of 0.5% SDS in 0.5 N NaOH. 700 µl of the lysate were used to monitor radioactivity, by liquid scintillation spectrometry (Betamatic, Kontron). The remaining 300 µl were used for protein content determination by the Lowry method (Lowry assay Kit, Sigma.) To correct for non-specific uptake or cell membrane binding, additional studies were performed in which aortic segments were incubated with 10 mM unlabeled arginine in HEPES buffer, and the associated radioactivity was subtracted from each data point. Results are expressed as mean ± SE of at least 5 different rats. In order to explore a possible association between the effect of rosiglitazone on arginine transport and PKC , arginine transport was determined in freshly harvested aortic rings from rosiglitazone treated uremic rats (group 3) following incubation with 50 nM of phorbol - Membranes were subsequently washed three times, for 5 min each, in PBS-T.
Membranes were then stripped and reprobed with monoclonal anti--actin antibodies as an internal control. The reactive bands corresponding to CAT-1 and PKC were detected by enhanced chemiluminescence (Kodak X-OMAT AR film) and quantified by densitometry. Three animals were utilized for each experimental group.
Immunoprecipitation studies
Aliquots of aortic tissue cell lysate (1 ml ) from the different experimental groups were After deparaffinization, heat-induced antigen retrieval was performed at a controlled temperature in a microwave processor (H2800 model, Energy Beam Sciences, Inc., MA, USA) in 10 mM citrate buffer, pH 6.0, for 10 min at 97°C. Immunohistochemistry was performed using a three-step indirect process based on the labeled-(strept) avidin-biotin (LAB-SA) peroxidase complex method. Sections were incubated at a controlled temperature of 37°C for 32 minutes with 1:100 dilution of anti nitrotyrosine antibodies.
Automated immunostaining was performed using the I-View DAB detection kit (Ventana Medical System) according to a standard Ventana program. The I-View DAB detection kit utilizes biotinylated secondary antibodies to locate the bound primary antibody, followed by the binding of Streptavidin-HRP (horseradish peroxidase) conjugate. The complex is then visualized with hydrogen peroxidase substrate and 3, 3'-diaminobenzidine (DAB) tetrahydrochloride chromogen, which produces a dark brown precipitate which is readily detected by light microscopy.
The sections were then counterstained with hematoxylin, dehydrated and mounted for microscopic examination. Tissues from three rats of each experimental group were processed.
Statistical Analysis
Data are presented as mean±SE. One way analysis of variance (Anova) was conducted for comparison between groups. Post-hoc analysis using LSD algorithm was performed to allocate the source of significance.
RESULTS
To consolidate previous observations and validate the therapeutic efficacy of rosiglitazone in our uremic model, Creatinine clearance (CCr), renal histology, urinary protein excretion, and aortic eNOS activity were measured in all experimental groups.
CRF resulted in a significant decrease in CCr (0.35±0.07 vs. 0.66±0.06 ml/min/100g BW, p<0.01). Administration of rosiglitazone had no effect on CCr in CRF animals (0.32±0.08 ml/min/100g BW). In addition no improvement in renal histology was noted (data not shown). In contrast, protein excretion was significantly decreased in CRF rats by the administration of rosiglitazone (figure 1). We measured cGMP generation following stimulation with Carbamyl Choline (CCh), a selective eNOS agonist, in order to examine aortic eNOS activity. CCh stimulated cGMP levels were significantly decreased in uremic rats as compared to control animals and administration of rosiglitazone significantly attenuated this phenomenon (figure 2).
Effects of rosiglitazone on aortic arginine transport in uremia
In similar to our previous observation, CRF induced a significant (~50%) decrease in aortic arginine uptake when compared to sham operated animals. Treating CRF rats with rosiglitazone completely abolished this effect ( figure 3 a ) . In order to prove that rosiglitazone exerts it's effect on arginine transport through activation of PPARs receptors, GW9662, a PPAR inhibitor was co-administered to rosiglitazone treated CRF rats. Indeed, GW9662 prevented the beneficial effect of rosiglitazone on arginine transport compared to vehicle treated animals (figure 3 b )
To further explore the effect of decreased arginine uptake on the endothelium in CRF, we employed Western blotting and immunohistochemistry to evaluate protein nitration. 
Regulation of aortic CAT-1 protein in rosiglitazone treated uremic rats
To determine whether rosiglitazone induced changes in arginine uptake are associated with parallel directional changes in CAT-1, CAT-1 protein levels were evaluated. CAT-1 protein was identified as ~90 kDa. We found that CAT-1 abundance was significantly decreased in aortic rings harvested from CRF rats and this was not affected by rosiglitazone administration (figure 6).
In The present study demonstrates that rosiglitazone prevents the decrease in aortic arginine transport characteristic of CRF through PPAR activation, thus providing a novel mechanism to explain its beneficial effect on endothelial function in uremia.
It has been shown, predominantly regarding to inducible and neuronal NOS, That the consequences of decreased arginine transport are far beyond a mere substrate depletion.
NOS enzymes contain four redox active prosthetic groups (FAD, FMN, We have tried to elucidate a molecular mechanism to explain our findings. The fact that rosiglitazone related changes in arginine uptake were not associated with changes in CAT-1 protein content, strongly support the notion that these events involve a post translational CAT-1 modulation. We were therefore intrigued to explore a putative Moreover, during pregnancy, treatment with -tocopherol, which inhibits PKC, prevents the decrease in arginine transport (17) . We have decided to focus exclusively at the membrane fraction of PKC , since this is where the interaction between this enzyme and CAT-1 occurs. Similar to our findings in hypercholesterolemia and pregnancy, we found in the current set of experiments a significant increase in the aortic membrane bound fraction of PKC which was associated with a significant increase in CAT-1 phosphorylation. Both findings were attenuated by rosiglitazone. Interestingly, PKC phosphorylation was unchanged in CRF. Yet, the administration of rosiglitazone significantly decreased it's phosphorylation. In addition, ex-vivo exposure of aortic rings harvested from rosiglitazone treated uremic rats to PMA (a PKC stimulant ) abolished it's beneficial effect. These data establish that in CRF the increase in PKC activity is primarily derived form it's translocation from the cytosol to the cellular membrane while administration of rosiglitazone mitigates the decrease in arginine transport during uremia through modulation of both subcellular distribution and activation of PKC . PPAR mediated inhibition of classical PKCs has been previously described. Verrier et al have
shown that PPAR agonists inhibit the diacylglycerol-protein kinase C signaling pathway (29) , while Von Knethen et al have recently suggested that PPAR ligand activation attenuates cytosol to membrane translocation of PKC in macrophages (30) . While there is a growing bulk of evidence suggesting that inflammation contributes substantially to the pathogenesis of CKD, it is surprising that the role of PKC has not been extensively studied in uremia. Wolf et al reported that, in uremic rats, PKC protein content is augmented in the myocardium (33) . We believe that the role of PKC activation in CRF and it's effects on the endothelium deserve further attention.
We have previously shown that in uremia, the decrease in arginine transport is associated with decreased CAT-1 protein abundance and treatment with either atorvastatin or arginine prevents the decline in arginine uptake and restores CAT-1 protein content (24) .
In the current experiments, rosiglitazone prevented the decrease in arginine transport without affecting CAT-1 protein. These findings allow us to dissect two different mechanisms which impact arginine transport in CRF. The first is associated with a decrease in CAT-1 translation, while the second evolves from upregulation of PKC .
The ability to restore normal arginine velocities in the presence of decreased CAT-1 protein abundance suggests that the latter is the dominant one. 
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